Filing Flows › Spero Therapeutics (SPRO) › Q4 2025
Spero Therapeutics (SPRO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Spero Therapeutics (SPRO) reported revenue of $41.3M for the fourth quarter 2025 (Q4 2025), +175% from a year earlier and +659% from the quarter before. Operating margin was 76.0%, net earnings $31.5M (76.3% of revenue).
Spero Therapeutics, Q4 2025: revenue $41.3M (+174% year over year), operating margin 76.0%, net earnings $31.5M, operating cash flow −$8.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.3M | +659% | +175% |
| Operating profit | $31.4M | — | — |
| Net earnings | $31.5M | — | — |
| Operating cash flow | −$8.4M | -148% | — |
What changed
Revenue was $41.3M in Q4 2025, up 175% year over year and up 659% from the previous quarter. Collaboration Revenue Related Party was the largest line at 66% of revenue.
Operating profit was $31.4M, a 76.0% margin (up 220.5 points year over year). Total costs fell 73% while revenue rose 175%. Net earnings were $31.5M. The effective tax rate was 0.8%.
Operating cash flow was −$8.4M. Non-cash charges added back $1.0M of share-based compensation. Working capital and other items used $40.9M.
Questions
What was Spero Therapeutics' revenue in the fourth quarter 2025?
Spero Therapeutics (SPRO) reported revenue of $41.3M for the fourth quarter 2025 (Q4 2025), +175% from a year earlier and +659% from the quarter before.
Was Spero Therapeutics profitable in the fourth quarter 2025?
Operating profit was $31.4M (76.0% of revenue) and net earnings $31.5M.
Source: Spero Therapeutics 10-K on SEC EDGAR.